Q4 2024 Earnings Summary
- Dentsply Sirona is well-positioned to capitalize on the underpenetrated digital dentistry market globally, with significant growth opportunities in scanners—the entry point for digital workflows—where even in developed markets like Germany, only 27% of practices have an intra-oral scanner. The company's end-to-end digital solutions enable customers to be more efficient, address staffing shortages, and grow their practices.
- Management is taking concrete steps to improve underperforming areas such as Implants by enhancing digital connectivity through DS Core, focusing on local clinical education, simplifying messaging, and improving sales force capabilities. These initiatives are expected to drive improved performance in Implants this year.
- Despite the decline in Byte revenues, the company expects adjusted EPS growth in 2025 due to cost savings from reduced investments, particularly in marketing. Management anticipates margin expansion over the year, with potential upside from back-office transformation efforts not yet included in the 2025 plan.
- Unresolved German tax dispute creates uncertainty: The company has no meaningful update on the German tax situation, with resolution likely to take a while. This lingering issue could pose financial risks.
- Softness in key markets despite new product launches: Despite launching Primescan 2, the company's new scanner, there is continued softness in retail CAD/CAM sales in the U.S. The macro environment is pressurizing customers, and dental practices may be reticent about investing in capital equipment. The company expressed disappointment with CAD/CAM performance.
- Underperformance in the U.S. implant business: Implant sales in the U.S. have disappointed over the past two years. Challenges include complex messaging and recent additions to the sales team, which may hinder the company's ability to return to growth in this important segment.
| Metric | YoY Change | Reason |
|---|---|---|
Total Revenue | -10.6% (from USD 1,012M to USD 905M) | Total revenue declined sharply in Q4 2024, driven largely by weaker overall sales, particularly in the U.S., which dragged down aggregate performance compared to Q4 2023. |
U.S. Segment Revenue | -30% (from USD 368M to USD 258M) | U.S. revenue experienced a significant drop likely due to deteriorating market conditions, reduced demand, and possibly unfavorable product mix or regulatory pressures that sharply contrasted with previous stronger performance. |
European Revenue | +2.8% (from USD 397M to USD 408M) | European revenue showed modest growth, indicating a more stable regional performance that counterbalanced the U.S. decline, though the reasons likely reflect differences in market dynamics and consumer demand between regions. |
Operating Income (EBIT) | From +USD 73M to -USD 509M | Operating income reversed its trend dramatically from a positive figure to a large loss, suggesting the impact of increased cost pressures, impairments or operational inefficiencies that eroded margins compared to Q4 2023. |
Net Income | From +USD 72M to -USD 430M | Net income shifted from a modest profit to a substantial loss, reflecting the combined effects of reduced revenue and the negative impact of steep operating losses and adverse non-cash adjustments, relative to the prior period. |
Adjustments for Non-Cash Items | From -USD 12M to +USD 1,276M | Non-cash adjustments surged dramatically, likely due to significant non-cash charges such as impairments, changes in deferred taxes, or other accounting adjustments that were minimal or negative in Q4 2023, thereby impacting reported cash flow dynamics. |
Share Repurchases | From USD 15M to USD 250M | Share repurchases jumped considerably, reflecting a strategic shift in capital allocation enabled by an increased repurchase authorization and potentially favorable market conditions, contrasting markedly with the much lower level in Q4 2023. |
| Metric | Period | Previous Guidance | Current Guidance | Change |
|---|---|---|---|---|
Organic Sales | FY 2025 | no prior guidance | Expected to decline by 2% to 4% | no prior guidance |
Net Sales Range | FY 2025 | no prior guidance | Projected to be between $3.5 billion to $3.6 billion | no prior guidance |
Foreign Exchange Impact | FY 2025 | no prior guidance | Expected to be a headwind to reported sales based on current rates | no prior guidance |
EBITDA Margin | FY 2025 | no prior guidance | Anticipated to be greater than 18% | no prior guidance |
Adjusted EPS | FY 2025 | no prior guidance | Expected to be in the range of $1.80 to $2.00 | no prior guidance |
Q1 2025 Organic Sales | Q1 2025 | no prior guidance | Expected to decline high single digits year-over-year | no prior guidance |
Tax Rate | FY 2025 | no prior guidance | Projected increase in the full-year tax rate due to geographic income mix and unfavorable performance trends | no prior guidance |
| Metric | Period | Guidance | Actual | Performance |
|---|---|---|---|---|
Full-Year 2024 Net Sales | FY 2024 | $3.79B to $3.82B | $3.793B (sum of Q1–Q4 2024) | Met |
| Topic | Previous Mentions | Current Period | Trend |
|---|---|---|---|
Digital Dentistry and Scanner Technology | Q1: Emphasis on DS Core and Primescan Connect boosting digital workflows. Q2: Noted strong performance from Primescan Connect despite product‐mix challenges. Q3: Primescan 2 launched with >900 global units and mid‐single digit CAD/CAM growth. | Q4: U.S. CAD/CAM experienced a double‐digit decline due to softer retail demand, while Germany showed growth; Primescan 2 boosted DS Core subscriptions and enhanced product integration. | Recurring with regional segmentation: Continued emphasis on digital dentistry but with diverging sentiment—weak U.S. performance versus strength in Germany. |
Implant Business Performance and Improvement Initiatives | Q1: Delivered low single‐digit global growth with strong China performance and value implant momentum. Q2: Noted over 30% growth in China, offset by U.S./Europe declines and mixed performance. Q3: Cited execution issues and U.S./European challenges along with referral network struggles. | Q4: Reported high single‐digit organic decline; introduced the MIS LYNX implant in the U.S. and outlined a digitalization strategy via DS Core with localized education initiatives. | Recurring with increased focus on digital transformation: Persistent U.S. challenges are being met with a deep dive into digital connectivity and tailored sales training. |
Aligner Business Dynamics | Q1: Byte and SureSmile showed healthy growth figures with strong impression kit conversions. Q2: Legislative changes forced Byte’s revised growth forecast to 15% and adjustments to the go‐to‐market model. Q3: Byte faced suspension, regulatory review, and operational challenges. | Q4: The company decided to write off the Byte trademark and redeploy its R&D and e‑commerce resources to the SureSmile platform, which showed steady growth and enhanced software improvements. | Shift away from Byte toward SureSmile: Evolving regulatory and market challenges have led to discontinuing Byte and refocusing on SureSmile for future growth. |
Cost Control, Restructuring, and Margin Expansion Initiatives | Q1: Focused on tightening cost controls and started restructuring measures to deliver margin improvements. Q2: Announced Phase 1 savings and introduced a Phase 2 restructuring plan targeting $80–100 million annually. Q3: Reported progress in restructuring programs with sequential margin improvements despite challenging product mix. | Q4: Continued transformational efforts aiming for $80–100 million in savings with further operational efficiency initiatives and reinvestment in growth areas, aiming for improved EBITDA margins by Q1 2025. | Consistent focus with incremental savings: The company remains on track with cost control and restructuring initiatives, which are gradually bolstering margins. |
Connected Technology Solutions (CTS) and Imaging Equipment Performance | Q1: CTS faced a 5.7% organic sales decline driven by imaging equipment headwinds, though the CAD/CAM segment performed well. Q2: Reported double‐digit declines in E&I and CAD/CAM, alongside a relaunch of Orthophos SL in Germany. Q3: Noted strong Primescan 2 launch but continued challenges in imaging due to macro headwinds. | Q4: While the CTS segment in the U.S. continued to struggle with soft retail demand, the Imaging segment posted nearly 13% global growth driven by the Orthophos relaunch and Primescan 2, signaling product‐level recovery. | Mixed performance: Imaging is recovering strongly while broad CTS remains challenged by regional variations and external market pressures. |
Macroeconomic Headwinds Impacting Capital Equipment Demand and Revenue | Q1: High interest rates and unfavorable economic conditions led to soft demand, particularly in imaging, contributing to a 1.9% organic sales decline. Q2: Macro headwinds resulted in double‐digit declines in equipment segments (E&I and CAD/CAM). Q3: Continued soft demand with compressed capital investment and persistent high rates. | Q4: Ongoing macroeconomic pressures continue to hamper U.S. capital equipment sales, although Germany shows better performance; outlook remains cautious despite some regional recoveries. | Persistent negative sentiment: Macroeconomic challenges continue to dampen equipment investments overall, although some regional rebounds (e.g., Germany) are emerging. |
New German Tax Dispute and Financial Uncertainty | Q1 and Q2: Not discussed. Q3: Emerging concerns as tax investigators visited facilities, raising uncertainty about the tax dispute in Germany that represents about 10% of business. | Q4: No meaningful update was provided; the company continues to engage with German authorities, maintaining a cautious yet unresolved stance. | Recurring but muted: The tax dispute remains a concern, but Q4 discussion was less detailed, suggesting the issue is still under review with limited new information. |
Legislative Changes Impacting the Direct-to-Consumer Aligner Market | Q1: Not mentioned. Q2: Legislative changes required adjustments in the Byte model, leading to a downward revision of growth forecasts to approximately 15%. Q3: Faced significant regulatory challenges triggering a voluntary suspension of Byte operations. | Q4: There was no new mention of legislative changes affecting the aligner business in the earnings call. | Declining discussion: After heightened regulatory focus in Q2 and Q3, the topic was not mentioned in Q4, indicating a reduced emphasis or a settlement of issues. |
New Product Launches and Pipeline Execution Risks | Q1: Emphasized DS Core adoption, reintroduced Orthophos SL, and began new product announcements, including imaging and workflow enhancements. Q2: Announced planned digital equipment launches and updates to key imaging lines. Q3: Achieved several new launches (Primescan 2, X-Smart Pro+), bolstering the innovation pipeline. | Q4: Continued robust product introductions with the U.S. launch of the MIS LYNX implant and the launch of Primescan I; highlighted 6 out of 8 innovations cleared in 2024 and a pipeline of 20+ new products through 2026, while noting execution risks amid market challenges. | Consistently robust innovation pipeline: The focus on new product launches remains strong, with continuous efforts to drive digital connectivity and mitigate execution risks despite external pressures. |
-
Byte Strategy and P&L Impact
Q: What's the strategy for Byte after writing off its brand name?
A: The company is redeploying Byte's capabilities into the SureSmile platform, focusing exclusively on SureSmile aligners. Byte's deep expertise in demand generation, e-commerce, and patient experience is being leveraged to enhance SureSmile's user interface and experience. This shift is expected to result in significant cost savings, particularly in marketing expenses, and may provide a tailwind to earnings despite a projected revenue decline of under $40 million in 2025. -
Margin Outlook and Cost Initiatives
Q: How confident are you in margin improvement and cost control?
A: Margins are expected to improve sequentially throughout the year, with Q1 being the lowest point due to pressure from Byte's impact. Foundational initiatives will ramp up in later quarters. Additionally, a back-office transformation is underway, potentially offering upside in 2025 and longer-term benefits into 2026 and 2027. -
German Tax Situation Update
Q: Any update on the German tax issue?
A: There is no meaningful update at this time. The company continues to work with German authorities, providing information and responding to requests. They believe the issues identified by the authorities do not exist and are difficult to estimate a resolution timeline. -
U.S. Implants Performance
Q: What's causing the decline in U.S. implant sales?
A: The U.S. implant business has underperformed expectations over the past two years. To address this, the company completed a deep dive and is launching digital connectivity for implants on DS Core, aiming to fully digitalize the implant business. They are also focusing on local-level education programs and simplifying their complex messaging to customers. Sales force capabilities are being recalibrated with added training, and performance improvement is expected this year. -
SureSmile Performance in U.S.
Q: Why is SureSmile down double digits in the U.S.?
A: The decline is attributed to legacy products within the SureSmile category, which make up about 20–25% of the business. The true aligner business has posted four quarters of high single-digit to double-digit growth in 2024. Excluding unique losses previously shared, the aligner business alone is growing mid-single digits in the U.S., with solid growth in the general practitioner segment. -
G&A Cost Benchmarking
Q: What's the potential benefit from the G&A cost initiatives?
A: The company acknowledges that parts of the business, especially back office, are over-indexed relative to industry averages. Simplifying processes and eliminating duplicative efforts are expected to unlock value over time, potentially impacting 2025 and beyond. Specific benchmarks for G&A as a percent of sales were not disclosed. -
Dental Utilization Trends
Q: What are the current dental utilization trends across key markets?
A: Patient volumes impacting Equipment and Consumables (EDS) are globally stable based on a survey of about 1,400 respondents. Germany, while still negative, shows signs of optimism with increased appetite for investments, particularly in the CTS business. Staffing shortages remain a significant issue worldwide, and the company aims to offset this with digital solutions and workflow efficiency. -
Softness in CAD/CAM Sales
Q: Why isn't Primescan 2 resonating better in the U.S.?
A: The macro environment in North America remains challenging, with dental practices hesitant to invest in capital equipment due to compressed reimbursements and patients' reduced spending on elective procedures. While imaging performed well, CAD/CAM sales were disappointing. The company does not attribute the softness to relationships with distributors like Patterson but rather to broader economic pressures. -
Distributor Being Taken Private
Q: Does a primary wholesaler going private affect your business?
A: There is no expected disruption. The company maintains strong relationships with distributors, partnering at both field and management levels. Distributors continue to order products, and the company remains a meaningful component of their business. The digital solutions provided enable customers and distribution partners to be successful. -
Germany's Market Experience
Q: What lessons does Germany's experience offer for global strategy?
A: In Germany, reintroducing a mid-priced offering (Orthophos SL) and focusing on execution discipline within the imaging team led to growth. The company emphasizes that enhancing sales team capabilities through training in professional selling skills and clinical conversations is as crucial as product offerings. This approach is being replicated in the U.S. to improve performance.
Research analysts covering DENTSPLY SIRONA.